Voloridge Investment Management LLC Increases Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Voloridge Investment Management LLC raised its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 150.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 340,953 shares of the company's stock after buying an additional 204,911 shares during the period. Voloridge Investment Management LLC's holdings in Takeda Pharmaceutical were worth $4,514,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also modified their holdings of the company. Blair William & Co. IL boosted its holdings in Takeda Pharmaceutical by 8.1% during the 4th quarter. Blair William & Co. IL now owns 12,199 shares of the company's stock valued at $162,000 after acquiring an additional 913 shares during the period. Sage Rhino Capital LLC boosted its stake in shares of Takeda Pharmaceutical by 14.9% in the fourth quarter. Sage Rhino Capital LLC now owns 11,840 shares of the company's stock valued at $157,000 after purchasing an additional 1,538 shares during the period. Vident Advisory LLC grew its holdings in shares of Takeda Pharmaceutical by 13.5% in the fourth quarter. Vident Advisory LLC now owns 13,606 shares of the company's stock valued at $180,000 after purchasing an additional 1,616 shares in the last quarter. OLD Mission Capital LLC grew its holdings in shares of Takeda Pharmaceutical by 13.7% in the fourth quarter. OLD Mission Capital LLC now owns 13,977 shares of the company's stock valued at $185,000 after purchasing an additional 1,687 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its stake in Takeda Pharmaceutical by 51.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 5,190 shares of the company's stock worth $69,000 after buying an additional 1,770 shares during the period. 9.17% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley upgraded shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Up 1.4%

NYSE TAK traded up $0.21 during trading hours on Friday, hitting $15.01. 1,724,832 shares of the company were exchanged, compared to its average volume of 1,999,445. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63. The firm has a market cap of $47.76 billion, a price-to-earnings ratio of 37.53, a PEG ratio of 0.24 and a beta of 0.26. The company has a 50 day moving average of $14.66 and a two-hundred day moving average of $14.04. Takeda Pharmaceutical Company Limited has a 52-week low of $12.57 and a 52-week high of $15.43.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.08). Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. The firm had revenue of $7.34 billion during the quarter, compared to analyst estimates of $8.02 billion. Equities research analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.